ENOB - Enochian Biosciences Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.1300
-0.3800 (-10.83%)
As of 2:49PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close3.5100
Open3.4100
Bid3.1100 x 1100
Ask3.1200 x 3000
Day's Range3.0499 - 3.4200
52 Week Range2.9100 - 7.5000
Volume43,580
Avg. Volume89,931
Market Cap144.947M
Beta (5Y Monthly)-0.63
PE Ratio (TTM)N/A
EPS (TTM)-0.1730
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Enochian Biosciences Announces FDA INTERACT Meeting for a Potential Cure for HIV

    FDA has granted Enochian an INTERACT meeting for its innovative approach to autologous stem cell transplantation as a potential cure for HIV. INTERACT is the first available FDA interaction and is a key step in the process towards an Investigational New Drug (IND) to study first-in-human products leading to potential marketing approval. LOS ANGELES, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Enochian Biosciences, a company focused on genetically modified cellular and immune therapy for infectious diseases and cancer, announces that the FDA has scheduled an Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) meeting for early June.

  • GlobeNewswire

    Enochian Biosciences Acquires an Exclusive License for a Novel Hepatitis B Virus Potential Treatment or Cure

    Enochian Biosciences, a company focused on gene-modified cellular therapy in infectious diseases and cancer, announces that it has finalized the acquisition of a novel Hepatitis B Virus (HBV) potential treatment or cure from Seraph Research Institute. At that time, there were no therapies for Hepatitis B. Since that time, I have overseen the development and licensure of several major therapies for the treatment of Hepatitis B and HIV.

  • GlobeNewswire

    Enochian Biosciences, a company focused on gene-modified cellular therapy in infectious disease and cancer, announces the appointment of two board members:

    At Gilead, Mr. Alton has been Chief Patient Officer and Executive Vice President of International Operations and Corporate Affairs, Executive Vice President of Corporate and Medical Affairs, Secretary and Chief Compliance Officer and General Counsel. Through these and other positions, he was deeply engaged in growing Gilead from a small biotech to one of the largest pharmaceutical companies in the world.

  • GlobeNewswire

    Enochian Biosciences Announces Scientific Presentation of a Novel Approach to Potentially Cure Hepatitis B Virus

    A new gene therapy kills up to 98 percent of HBV infected cells but not uninfected cells. Results from a commonly used mouse model to study HBV confirmed the HBV-infected cell-specific killing effect of the novel therapy. LOS ANGELES, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Enochian Biosciences, a company focused on gene-modified cellular therapy in infectious disease and cancer, announces that important scientific findings reveal an innovative approach to potentially treat and cure Hepatitis B.

  • GlobeNewswire

    Enochian Biosciences Expands its Infectious Disease Pipeline by Entering into an Agreement in Principle to Acquire an Exclusive License for a Novel Hepatitis B Virus Treatment

    Enochian Biosciences, a company focused on gene-modified cellular therapy in infectious disease and cancer, announces the expansion of its infectious disease pipeline by entering into an agreement in principle to acquire an exclusive, license for a treatment under development aimed to treat the Hepatitis B Virus (HBV) infections from G-Tech Bio, LLC.  An abstract accepted for presentation at the HepDART meeting featuring in vivo and in vitro data from preclinical studies conducted with this novel HBV treatment candidate will be presented by Dr. Serhat Gümrükcü, MD, PhD on December 10, 2019. Approximately 5 percent of the world’s population is infected with HBV, and around 1 million people per year die from the disease.

  • Enochain Investor Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Enochain Biosciences Inc. To Contact The Firm
    Newsfile

    Enochain Investor Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Enochain Biosciences Inc. To Contact The Firm

    New York, New York--(Newsfile Corp. - November 21, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Enochain Biosciences, Inc. (NASDAQ: ENOB) ("Enochain" or the "Company").Faruqi & Faruqi logoIf you invested in Enochain stock or options and would like to discuss your legal rights, click here: www.faruqilaw.com/ENOB. There is no cost or obligation to you.You can also contact us by calling Richard Gonnello toll free ...

  • We're Not Very Worried About Enochian Biosciences's (NASDAQ:ENOB) Cash Burn Rate
    Simply Wall St.

    We're Not Very Worried About Enochian Biosciences's (NASDAQ:ENOB) Cash Burn Rate

    Just because a business does not make any money, does not mean that the stock will go down. For example, although...

  • GlobeNewswire

    Enochian BioSciences Inventor Named to Two Important Scientific Committees

    Enochian Biosciences is a pre-clinical stage biotechnology company committed to using its genetically modified cellular and immune-therapy technologies to prevent or potentially cure HIV and to potentially provide life-long cancer remission of some of the deadliest cancers.

  • Enochian Biosciences (NASDAQ:ENOB) Shareholders Have Enjoyed A 37% Share Price Gain
    Simply Wall St.

    Enochian Biosciences (NASDAQ:ENOB) Shareholders Have Enjoyed A 37% Share Price Gain

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! These days it's easy to simply buy an index fund, and your returns should (roughly) match the m...

  • GlobeNewswire

    Successful Treatment of “London Patient” Underscores Clinical Potential of Enochian Biosciences’ Gene Modified Cellular Therapy for HIV

    As with “the Berlin patient,” the first person to be considered “cured” of HIV a decade ago, the intervention utilized in the London patient was performed primarily to treat an HIV-associated cancer.  Both patients received transplants with cells from allogeneic donors who have a naturally occurring mutation (CCR5D32) which makes the individuals’ T cells resistant to infection by many types of HIV.  These allogeneic bone marrow transplantation procedures require myeloablative chemotherapy, a radical intervention that carries significant medical risks and considerable expense. Given the success of anti-retroviral medicines in managing HIV, this approach is not considered a medically necessary or viable treatment option for HIV-positive persons who do not already require an allogeneic transplant to treat another disease, such as cancer.